Published in final edited form as:

Drug Alcohol Depend. 2012 July 1; 124(1-2): 11–18. doi:10.1016/j.drugalcdep.2012.01.021.

Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: A novel treatment strategy

Tong H. Lee^{a,*}, Steven T. Szabo^a, J. Corey Fowler^d, Paolo Mannelli^a, O. Barry Mangum^e, Wayne F. Beyer^f, Ashwin Patkar^a, and William C. Wetsel^{a,b,c}

^aDepartment of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, United States

^bDepartment of Cell Biology, Duke University Medical Center, Durham, NC 27710, United States

^cDepartment of Neurobiology, Duke University Medical Center, Durham, NC 27710, United States

^dDuke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, United States

^eDuke Clinical Research Unit, Duke University Medical Center, Durham, NC 27710, United States

^fDuke Translational Research Institute, Duke University Medical Center, Durham, NC 27710, United States

Abstract

Psychostimulant abuse continues to present legal, socioeconomic and medical challenges as a primary psychiatric disorder, and represents a significant comorbid factor in major psychiatric and medical illnesses. To date, monotherapeutic drug treatments have not proven effective in promoting long-term abstinence in psychostimulant abusers. In contrast to clinical trials utilizing monotherapies, combinations of dopamine (DA) agonists and selective 5-HT₃, 5HT_{2A/2C}, or NK₁ antagonists have shown robust efficacy in reversing behavioral and neurobiological alterations in animal models of psychostimulant abuse. One important temporal requirement for these treatments is that the 5-HT or NK₁ receptor antagonist be given at a critical time window after DA agonist administration. This requirement may reflect a necessary dosing regimen towards normalizing underlying dysfunctional neural circuits and “addiction memory” states. Indeed, chronic psychostimulant abuse can be conceptualized as a consolidated form of dysfunctional memory maintained by repeated drug- or cue-induced reactivation of neural circuit and subsequent

© 2012 Elsevier Ireland Ltd. All rights reserved.

*Corresponding author at: Department of Psychiatry and Behavioral Sciences, Box 3870, Duke University Medical Center, Durham, NC 27710, United States. Tel.: +1 919 684 4374; fax: +1 919 681 8369. tong.lee@duke.edu (T.H. Lee).

Contributors

Dr. Lee wrote the initial draft and Dr. Szabo was responsible for integrating all co-authors feedback. All authors provided feedback on the manuscript and approved the final version.

Conflict of interest

Drs. Lee, Szabo, Fowler, and Wetsel have no financial disclosures or conflicts of interest. Dr. Patkar is a Consultant for Gilead, Dey Pharma and Transtek Pharma; is on the Speaker's Bureau and received honoraria from Alkermes, Bristol-Myers Squibb, Dey Pharma, Merck, Sunovion and Pfizer, has received Grant Support from National Institutes of Health (NIDA, NIAAA), SAMHSA, AstraZeneca, Bristol-Myers Squibb, Cephalon, Forest, J & J, Jazz Pharmaceuticals, Lundbeck, Merck, Organon, Pfizer, Sunovion, Shire and Titan. He is not a major stockholder or employed by or received other material support from pharmaceutical companies. Dr. Paulo Mannelli has received support from AstraZeneca, Bristol-Myers Squibb, Cephalon, Forest, GlaxoSmithKline, Janssen, Jazz Pharmaceuticals, King Pharmaceuticals, Lundbeck, McNeil Consumer and Specialty, Merck, Organon, Orphan Medical, Pfizer, Reckitt Benckiser, Titan. Dr. Beyer serves as an independent contractor for the Duke Translational Research Institute and has no financial interests or potential conflicts of interest.

reconsolidation. According to this concept, the DA agonist given first may reactivate this memory circuit, thereby rendering it transiently labile. The subsequent antagonist is hypothesized to disrupt reconsolidation necessary for restabilization, thus leading progressively to a therapeutically-mediated abolishment of dysfunctional synaptic plasticity. We propose that long-term abstinence in psychostimulant abusers may be achieved not only by targeting putative mechanistic pathways, but also by optimizing drug treatment regimens designed to disrupt the neural processes underlying the addicted state.

Keywords

Cocaine; Methamphetamine; Synaptic plasticity; Addiction; Substance abuse; Pharmacological treatment

1. Psychostimulant addiction

Psychostimulant abuse and dependence continue to exert profound socioeconomic, legal and medical problems throughout the world. In the United States (US), a recent survey (SAMHSA, 2009) estimated that 49.4 million or 21.2% of individuals aged 12 years or older had used cocaine or methamphetamine (METH) during their lifetime. Among ~6.1 million US residents who had used these two drugs in the past year, 722,000 persons had used cocaine for the first time, while the number for METH was 95,000 (SAMHSA, 2009). Treatment program admissions in 2007 for persons with primary cocaine or METH abuse accounted for 21% of 1,817,517 total admissions (SAMHSA, 2008), while psychostimulant-related emergency-department visits accounted for 33.9% of visits due to illicit drug use (SAMHSA, 2010). Compared to the US, a recent report by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA, 2010) estimated that 14 and 12 million Europeans used cocaine and amphetamines (i.e., amphetamine and METH) at least once in their lifetime, respectively. Among these users, 4 and 2 million individuals used the respective drugs during the past year. In contrast to North American and European countries, amphetamines, especially METH, represent the most commonly abused psychostimulant in the Pacific Rim countries including Japan, South Korea and Australia (Darke et al., 2007).

Psychostimulant dependence is not only a primary psychiatric disorder but also represents a significant comorbid factor for several major psychiatric disorders (Regier et al., 1990). For example, schizophrenic patients have higher degrees of psychostimulant abuse (15–60%) than the general US population (Miller and Tanenbaum, 1989; Dixon et al., 1991; Volkow, 2009). While an increased rate of psychostimulant abuse may partly represent an attempt to overcome aversive symptoms or treatment-related side-effects (e.g., “self-medication” hypothesis) or an increased psychostimulant sensitivity due to “dopaminergic supersensitivity” induced by chronic antipsychotic treatment (Khantzian, 1985; Gawin and Kleber, 1986; LeDuc and Mittleman, 1995; Fukushima et al., 2007), more recent studies have indicated potential mechanistic overlaps between psychostimulant abuse and other primary psychiatric disorders (see Volkow, 2009). Psychostimulants, especially the amphetamine derivatives, may induce psychotic states in mentally ill or vulnerable individuals (Connell, 1958; Ellinwood, 1968; Angrist and Gershon, 1970; Janowsky and Risch, 1979; Mahoney et al., 2008), and they may adversely affect the clinical course of psychiatric disorders (Janowsky and Davis, 1974; Drake and Wallach, 1989; Glasner-Edwards et al., 2010). Effective prevention and treatment strategies against psychostimulant abuse should facilitate overall management and improvement of prognosis for patients diagnosed with various psychiatric disorders. With respect to non-psychiatric sequelae, intravenous drug use and drug-induced behavioral disinhibition increases the risk of acquiring immune deficiency

syndromes, as well as hepatitis C, sexually-transmitted diseases, and various cardiovascular ailments (Gonzales et al., 2006; Colfax and Shoptaw, 2005; Cruickshank and Dyer, 2009).

2. Current state of pharmacotherapies for psychostimulant abuse

To date, more than two dozen medications have been tested in clinical trials as monotherapies against psychostimulant abuse. These drugs include clinically-available psychostimulants (e.g., dextroamphetamine or methylphenidate), selective serotonin reuptake inhibitors (e.g., fluoxetine) and other antidepressants (e.g., mirtazapine), full or partial DA agonists (e.g., pergolide, aripiprazole), atypical antipsychotic agents (e.g., risperidone), γ -aminobutyric acid (GABA) receptor agonists (e.g., gabapentin and baclofen), the analeptic modafinil. However, only a few have shown limited treatment efficacy, and none are FDA-approved for this indication. Bupropion, an antidepressant and smoking cessation aid, *n*-acetylcysteine, *d*-cycloserine, and the antiepileptic topiramate are also currently undergoing clinical investigations. Current medication development efforts for psychostimulant abuse have been recently reviewed (see Elkashef et al., 2008), and additional ongoing clinical trials can be found on the clinicaltrials.gov website (<http://www.clinicaltrials.gov/>). In addition to pharmacological treatments, cocaine vaccines have recently shown encouraging results (Kinsey et al., 2010), although this immunization strategy is still limited by the frequent dosing needed for efficacy, as well as a need for implementation of a clear vaccination policy (Hall and Gartner, 2011).

A potential explanation for unsatisfactory outcomes in monotherapeutic strategies, including psychostimulant vaccines, may be that these treatments are primarily designed to provide a “palliative” intervention, rather than directly targeting the dysfunctional neural processes underlying chronic psychostimulant use. Psychostimulant substitutes or “psychostimulant antagonists” are administered primarily to prevent the craving or reinforcing effects of the drug. These strategies may exert minimal effects on dysfunctional neurobiological states that underlie the continued psychostimulant use and vulnerability towards relapse in the addicted brain. Pathophysiologically-directed therapies, on the other hand, are likely to lead to an enhanced therapeutic outcome because they may reverse dysfunctional neurobiological processes and restore normal neural functions and behaviors. The present review describes a preclinical treatment strategy, which may lead to a more effective intervention and therapeutic outcome through the use of a temporally-spaced combination of two clinically-available drugs. Readers seeking more detailed discussions of potential mechanisms underlying psychostimulant abuse per se are referred to a comprehensive collection of reviews recently published in *Neuropsychopharmacology* (Vol. 33, January, 2008) as well as that by Koob and Volkow (2010).

3. Efficacy of combination treatment regimen in animal models

3.1. Overview

In contrast to sub-optimal results from monotherapeutic clinical trials, drug combination treatments have consistently shown to reverse behavioral and neurobiological alterations in behavioral sensitization and self-administration models of human psychostimulant abuse. Overall, we have demonstrated that a DA agonist in combination with a selective 5-HT₃, 5HT_{2A/2C}, or NK-1 receptor antagonist can consistently and robustly reverse *both* behavioral and neurobiological alterations in animal models of psychostimulant abuse (Davidson et al., 2002b,c, 2004, 2007; Zhang et al., 2007; Bhatia et al., 2011). When these combinations are administered under a specific dosing regimen for 5–7 consecutive days, these treatments (a) reverse previously-established cocaine or METH behavioral sensitization; (b) attenuate self-administration under progressive ratio and drug-induced reinstatement paradigms; and (c) normalize changes in associated neurobiological markers.

The DA agonists tested in the combination treatments include psychostimulants themselves (e.g., cocaine) and the “anti-Parkinsonian” agent pergolide. It is noted that pergolide is no longer available clinically due to its propensity to induce heart valvulopathy (Schade et al., 2007). The 5-HT agents that have shown preclinical efficacy include the 5-HT₃ antagonist ondansetron and the 5-HT₂ antagonist ketanserin, while the NK-1 antagonists include WIN51708. The 5-HT₃ antagonist ondansetron is used in clinics as an antiemetic agent, as is the recently-approved NK1 receptor antagonist aprepitant. Fig. 1 provides a brief overview of the sensitization and self-administration paradigms used in the above studies, and Table 1 presents selected neurobiological changes associated with established cocaine sensitization, which are normalized by a combination of pergolide and ondansetron administered under the dosing regimen described in the present review.

3.2. Reversal of behavioral sensitization

Psychostimulant behavioral sensitization following repeated intermittent exposure in animals is characterized by progressive increases in behavioral responsiveness to these drugs. Sensitization is considered a model of psychostimulant abuse and progression into compulsive use, especially when the drug is administered in dosing patterns that are designed to mimic those observed in compulsive high-dose human abusers (see Davidson et al., 2007; Steketee and Kalivas, 2011). Once consolidated through a few days of drug withdrawal, the increased behavioral responsiveness to psychostimulants is maintained even after long-term withdrawal. This long-term maintenance suggests that a stable dysfunctional “memory” is formed, and may underlie the remarkable relapse vulnerability in human abusers even after prolonged abstinence (Gawin and Ellinwood, 1988; Taylor and Gold, 1990; Shalev et al., 2002). Notably, sensitization has been accepted to model neuroadaptations associated with addiction to psychostimulant and other drugs of abuse (see Robinson and Berridge, 2008).

We first have demonstrated that consolidated behavioral sensitization in rodents can be reversed if the sensitized animals are treated daily with cocaine injections, and if each of these injections is followed 3.5 h later with an antagonist to 5-HT₃ (e.g., ondansetron) or 5-HT₂ (e.g., ketanserin) receptors (Davidson et al., 2002b,c, 2004). Behavioral efficacy of these combined DA agonist/5-HT antagonist regimens is especially striking considering that psychostimulants given alone during the same period further increases, rather than decreases, behavioral sensitization (Davidson et al., 2002a). Daily treatment with ondansetron alone is ineffective in reducing *consolidated* behavioral sensitization (Davidson et al., 2002c) although this monotherapy can reduce the sensitization expression – if it is administered during the first 5 days of cocaine withdrawal, before a full consolidation of behavioral sensitization (King et al., 2000). Additional 5-HT antagonists that have been shown to reverse cocaine sensitization when given after daily cocaine administration include clozapine (5-HT₃, 5-HT_{2A/2B} and other receptor subtypes), mianserin (5-HT_{2A/2C}), and WIN51708 (NK1; Davidson et al., 2002b, 2004). It is important to reiterate that the desired reversal of behavioral sensitization is achieved if, and only if, the antagonist is given after, but not before or simultaneously with the agonist (Davidson et al., 2002c).

Reversal of behavioral sensitization can be also achieved with combination treatment if the psychostimulants themselves are substituted with pergolide and followed 3.5 h later with ondansetron or ketanserin (Zhang et al., 2007; Davidson et al., 2007; Bhatia et al., 2011). Similar to that of psychostimulant treatments alone, daily treatments with pergolide alone are ineffective (Zhang et al., 2007; Davidson et al., 2007; Bhatia et al., 2011). In fact, pergolide alone tends to further increase the behavioral sensitivity to psychostimulants (Bhatia et al., 2011). This cross-sensitizing effect of chronic pergolide monotherapy may partially account for the variable therapeutic outcomes of this therapy with cocaine abusers (Malcolm et al., 2000; Levin et al., 1999). Moreover, in a controlled clinical study, pergolide

has also been shown to induce cocaine “craving” in abstinent cocaine abusers (Haney et al., 1998). In contrast to responsivity to cocaine or METH challenge, agonist/antagonist combination treatments do not alter either pre- or post-challenge “baseline” activity levels. Together with the normalization of sensitization-associated neurobiological markers (Table 1), these observations suggest that their effects on sensitized animals are likely to represent a true treatment effect, rather than nonspecific behavioral inhibition (e.g., lethargy) or a conditioned “hypolocomotor” response induced by the prior combination treatment. Either of these effects could “mask” sensitization following acute drug challenge (e.g., a new extinction memory competing with the expression of consolidated memory).

3.3. Attenuation of self-administration

In addition to behavioral sensitization, ondansetron given at a critical time window *after* daily cocaine self-administration sessions decreases the progressive ratio break-point measured on the next day, when the antagonist should be completely eliminated from the body (Davidson et al., 2002c). It should be noted that the break-point under progressive ratio paradigms is considered a measure of the “willingness to work” toward obtaining a given reinforcer by the animal, where a higher break-point signifies higher willingness. By contrast, a reduced break-point in the above preclinical studies suggests that combined cocaine (self-administration) and subsequent ondansetron treatment may be effective in reducing drug use in active cocaine abusers. Similarly, in an animal model of relapse, combined pergolide-ondansetron treatment after acquisition of a stable self-administration pattern has been demonstrated to attenuate subsequent cocaine- or METH-induced reinstatement under an extinction and reinstatement self-administration paradigm (Davidson et al., 2007). This attenuation suggests that targeted treatment of abstinent psychostimulant abusers may be effective in preventing future relapses that frequently occur upon drug re-exposure (Gawin and Ellinwood, 1988).

4. Role of acute psychostimulant withdrawal in maintaining psychostimulant abuse

Traditional facets of psychostimulant addiction have focused on positive reinforcing effects of these agents with molecular and neurochemical changes in critical brain circuits such as the mesoaccumbens DA and corticoaccumbens glutamate pathways. In contrast, the DA agonist/5-HT antagonist combination treatment described in the present review is based largely upon a hypothesis that repeated induction of aversive responses during psychostimulant withdrawal, rather than positive drug rewarding effects, plays a key role in long-term maintenance of relapse vulnerability in compulsive psychostimulant abuse (Koob and Le Moal, 2001; Davidson et al., 2002c; Zhang et al., 2007; Fukushima et al., 2011; see D’Souza and Markou, 2010 for detailed discussion on psychostimulant withdrawal). Psychostimulant withdrawal is often associated clinically with dysphoria, anhedonia, anergia and other depressive symptoms (Gawin and Ellinwood, 1988; Ellinwood and Lee, 1989; Foltin and Fischman, 1997; Newton et al., 2004; Leventhal et al., 2008). The intensity of the aversive withdrawal symptoms is correlated with increased subjective “high” induced by subsequent cocaine challenges (Newton et al., 2003; Sofuoglu et al., 2003), and is a strong predictor of poor treatment response (Mulvaney et al., 1999; Kampman et al., 2001). Consistent with these “stress-associated” symptoms, basal activity and stressor-induced activation of the hypothalamic–pituitary–adrenal axis (HPA) are exaggerated during cocaine withdrawal in both animals and humans (Sarnyai et al., 1998; Contoreggi et al., 2003; Mantsch et al., 2007). Furthermore, stress-induced HPA activation shares similar facets to withdrawal symptoms from psychostimulant abuse, and is predictive of cocaine relapse outcomes (Sinha et al., 2006).

The first few days of withdrawal from chronic psychostimulant administration in animals are associated with time-dependent behavioral and neurobiological changes. Pharmacological interference during this early withdrawal phase can prevent the consolidation of long-term behavioral and neurobiological alterations (King et al., 1998; Lee et al., 1999; Li et al., 2000). Furthermore, a spectrum of analogous behavioral stress measures (e.g., ultrasound vocalization) has been reported in animals within days of cocaine withdrawal (Barros and Miczek, 1996; Mutschler and Miczek, 1998; Costall et al., 1990; Fung and Richard, 1994; Koeltzow and White, 2003). Various terms such as “allosteric dysregulation” or “acute withdrawal” have been used to describe aversive neurobiological processes, which characterize acute psychostimulant withdrawal and may contribute to the maintenance of long-term psychostimulant sensitization and abuse (Koob and Le Moal, 2001; Davidson et al., 2002c; D’Souza and Markou, 2010). Interestingly, earlier studies by Kuribara (1994, 1995) demonstrated that administration of D₁ or D₂ antagonists 3 h after METH administration inhibited sensitization induction in rodents, thus suggesting that acute withdrawal may also play an important role in the development of psychostimulant abuse.

The putative role of repeated acute psychostimulant withdrawal in maintaining chronic psychostimulant abuse forms the hypothetical basis for the sequential DA agonist/5-HT antagonist combination regimen. Thus, a psychostimulant or psychostimulant substitute (e.g., pergolide) sharing a similar pharmacological profile with cocaine or METH is first given *therapeutically* to simulate the “drug-on” state (i.e., reactivation of the stable dysfunctional memory). An acute withdrawal state ensues with agonist clearance that can be subsequently blocked with a 5-HT₃, 5-HT_{2A/2C}, or NK-1 receptor antagonist given 3.5 h after agonist administration (Davidson et al., 2002a, 2004). The choice of antagonist is based on the significant roles that 5-HT₃, 5-HT_{2A/2C}, or NK-1 receptor subtypes play in various responses such as anxiety, psychosis, nociception, and cognition (Barnes et al., 1990; Grant, 1995). Ondansetron and other 5-HT₃ receptor antagonists, as well as, NK-1 antagonists are clinically approved as antiemetic agents for their “anti-aversive” effects. Ondansetron has also shown to be useful in the treatment of alcohol withdrawal (Johnson, 2010). By comparison, drugs with 5-HT₂ receptor affinity have been used in the treatment of anxiety disorders, obsessive compulsive disorder, and major depression (de Leeuw and Westenberg, 2008; Landén and Thase, 2006; Kent, 2000). While localization of the pharmacological action of these combination treatments awaits additional investigation, the prefrontal cortex (PFC) may be a major site of action for the effects of combination treatments. Thus, the PFC may provide key modulations of consolidated psychostimulant sensitization and self-administration through the corticostriatal glutamate pathway and projection to the ventral tegmental area via the laterodorsal and pedunculopontine tegmentum areas (see Steketee and Kalivas, 2011). Importantly, distinct distributions of 5-HT_{2A} and 5-HT₃ receptors and substance P (neurotransmitter for NK-1 receptors) have been demonstrated in the PFC (Jakab et al., 1997; Jakab and Goldman-Rakic, 2000). Although elucidation of specific “mechanisms” underlying the efficacy of 5-HT and NK-1 antagonists in the combination regimen awaits further investigation, it is interesting to note that extracellular and intracellular calcium signaling through receptor channels (5-HT₃) or “second messenger systems” (5-HT₂ and NK-1 receptors) play major roles in various biological processes including synaptic plasticity (see Berridge et al., 2003 for review).

The hypothesis that all of the above antagonists may specifically act upon agonist-induced withdrawal states to reverse the consolidated psychostimulant abuse memory is supported by the findings that these agents, when used alone, have minimal efficacy in reversing *consolidated* behavioral alterations in animal models of psychostimulant abuse. Heuristically, repeated therapeutic induction and blockade of psychostimulant withdrawal effects may provide a means to disassociate previously established relationships between the acute and aversive withdrawal effects of psychostimulants with that of long-term synaptic

dynamics. This dissociation, in turn, may underlie the long-term maintenance of abuse patterns in chronic psychostimulant abusers. Therefore, the rationale for agonist administration employed in the combination-treatment approach contrasts that of “typical” DA agonist treatments, which simply seek to provide positive “drugon” effects or to induce and maintain tolerance through chronic agonist administration (Ellinwood et al., 2002).

5. Clinical data on the efficacy of ondansetron monotherapy

The National Institute on Drug Abuse (NIDA) has conducted multi-center clinical trials to determine the efficacy of ondansetron monotherapy in maintaining abstinence in cocaine and METH abusers (Johnson et al., 2006, 2008). For cocaine abusers, the 5-HT₃ antagonist (4 mg/kg, b.i.d.) significantly reduced trial dropout rates and improved cocaine abstinence as verified by negative urine screening results (Johnson et al., 2006). Notably, the greatest treatment responses were observed in abusers who had the highest number of cocaine-positive urine samples before entering the trial, suggesting that this treatment exerted higher efficacy in subjects who had the highest frequencies of drug use. This positive correlation between the estimated pre-treatment level of cocaine use and the treatment response contrasts with those reported for most of the other treatments (e.g., modafinil; Anderson et al., 2009). These treatments were essentially more efficacious in cocaine users with low to moderate levels of dependence. Due to active cocaine use by these subjects, it could be hypothesized that the treatment-responsive subgroup may have been surreptitiously subjected to the aforementioned DA agonist/5-HT antagonist combination treatment (self-administered cocaine and ondansetron) and thus showed a positive treatment response. Since ondansetron was administered twice a day in this study and because the half-life of cocaine is 60–90 min in humans (Jeffcoat et al., 1989), many of these subjects may have frequently experienced 5-HT₃ blockade during the acute cocaine withdrawal period. In this regard, it should be recalled that neither consolidated behavioral sensitization nor self-administration can be reversed with ondansetron treatment alone (Davidson et al., 2002c).

In contrast to cocaine, ondansetron monotherapy was not effective for METH abusers (Johnson et al., 2008). While there are several potential reasons for this negative result (e.g., sub-optimal ondansetron doses, etc.), a major difference between effects of ondansetron on cocaine and METH abusers may relate to the much longer half-life of METH, being 6–24 h in humans (Cho et al., 2001) as compared to 60–90 min for cocaine (Jeffcoat et al., 1989). We hypothesize that the longer METH half-life may have resulted in a much narrower therapeutic time-window for the prescribed ondansetron to be taken during the time of acute METH withdrawal. Under such conditions, it is unlikely that ondansetron-mediated 5-HT₃ blockade would have occurred during the period of “reconsolidation” of the addiction memory in the course of acute METH withdrawal. These considerations provide further rationale for the proposed regimen-dependent DA agonist/5-HT antagonist treatments, whereby *both* the reactivation of the addiction circuit and blockade of its reconsolidation could be *therapeutically controlled* for disruption of the consolidated dysfunctional memory.

6. Neural basis of combination treatment efficacy

Various neuropsychiatric disorders are increasingly considered as a consolidated form of maladaptive synaptic plasticity (Kreitzer and Malenka, 2008; Pierce and Vanderschuren, 2010; Lewis and González-Burgos, 2008; Pittenger and Duman, 2008). Accordingly, treatment-mediated normalization of these neuroplastic changes may be expected to lead to a successful therapeutic outcome (Centonze et al., 2005). As illustrated in Fig. 2, chronic psychostimulant abuse can be also conceptualized as a consolidated (stable) form of dysfunctional memory with associated neurobiological changes (see Table 1), which is maintained by repeated cycles of reactivation and reconsolidation (see Centonze et al., 2005

for an overview on reconsolidation inhibition and extinction in psychiatric treatments). In untreated psychostimulant abusers, the stable memory could be reactivated by exposure to various stimuli such as psychostimulants themselves (“drug tasting,” unconditioned stimulus), environmental cues associated with drug use (e.g., drug paraphernalia or being near a “crack house,” conditioned stimuli) or “stress” (Jaffe et al., 1989; Childress et al., 1999; Sinha, 2001; Sinha et al., 2006), thus contributing to drug taking behaviors (i.e., relapse). Unless interfered with, reactivated memory is expected to become reconsolidated during withdrawal (e.g., “crash”).

As discussed in Centonze et al. (2005), treatment strategies which can disrupt or erase the established psychostimulant-abuse memory and, thereby, normalize the underlying neurobiological changes in *controlled clinical settings* may lead to successful therapeutic outcomes in chronic psychostimulant abusers. Within this context, we hypothesize that a DA agonist acting as a psychostimulant substitute therapeutically reactivates the consolidated psychostimulant abuse memory to render it transiently labile (Fig. 2). An antagonist given 3.5 h after the agonist (reconsolidation period) disrupts the circuit reconsolidation that is required for memory restabilization. According to this model, psychostimulant replacement through DA agonist monotherapy may be expected only to reactivate the memory, which would subsequently undergo a normal reconsolidation process. In contrast, a “psychostimulant antagonist” given alone may only prevent reactivation of the abuse circuit so that consolidated circuit remains in its original state, thereby abrogating therapeutically-mediated memory reactivation that is prerequisite for a successful treatment outcome. In addition to exposure to psychostimulants or substitutes, exposure to various conditioned stimuli associated with drug use may also reactivate the consolidated dysfunctional memory (Fig. 2). In fact, reactivation and reconsolidation processes has been most extensively investigated within the context of associations between conditioned and unconditioned stimuli (e.g., fear conditioning, drug-associated cues, etc.; see Nader and Hardt, 2009 for review). Several preclinical studies have now demonstrated that, similar to drug-induced reinstatement of self-administration, cue-induced reinstatement can be abolished by blocking reconsolidation (Lee et al., 2005; Bernardi et al., 2007; Kelley et al., 2007; Sadler et al., 2007; Fricks-Gleason and Marshall, 2008). In humans, a clinical study on effects of combined cue-exposure and propranolol on “memory for cocaine craving” has been completed (NCT00830362, clinicaltrials.gov). This nonselective beta-adrenergic receptor antagonist, which is used for treatment of cardiovascular disorders (e.g., hypertension, angina pectoris) as well as situational or performance anxiety, may be hypothesized to block the reconsolidation of the cue-reactivated memory. It is remarkable that, similar to the time interval between DA agonist and ondansetron, the reconsolidation of cue-induced reinstatement of cocaine self-administration has been reported to be susceptible to protein synthesis inhibitors within 4–6 h after cue exposure (Lee et al., 2006), indicating that a key temporal window after drug or cue exposure may be the period of memory reconsolidation requiring new protein synthesis. It may be interesting to hypothesize that a 5-HT or NK-1 antagonist might interfere with the new protein synthesis via their effects on Ca^{2+} -dependent transcriptional and/or translational events (see Section 4).

The combination pharmacotherapeutic approach reviewed herein is conceptually similar to the memory reactivation–degradation model that is being applied to other psychiatric disorders such as post-traumatic stress disorder (see Donovan, 2010). Furthermore, a recent human study has reported that disruption of the reconsolidated fear-conditioned memory can be best achieved when the experimental intervention interfering with reconsolidation is delivered ~3 h after the reactivation cue (Schiller et al., 2010). These considerations suggest that a *critical temporal window of opportunity exists for therapeutic “erasure”* of the dysfunctional memory associated with psychostimulant abuse. It should be also considered that even after a successful therapeutic outcome, genetic and/or environmental

predispositions may render many individuals at an increased risk to “reacquire” psychostimulant addiction. Thus, a comprehensive strategy against chronic, repeated psychostimulant abuse should include therapeutic measures designed to prevent reestablishment of dysfunctional “psychostimulant memory.”

7. A proof-of-concept clinical trial

A translational proof-of-concept Phase II clinical study sponsored by NIDA (NCT01377662, clinicaltrials.gov) is ongoing to determine the efficacy of a combination of immediate-release methylphenidate as the DA agonist (“psychostimulant substitute”) and a novel delayed, pulsatile-released ondansetron formulation for treatment of psychostimulant abuse. In normal healthy volunteers, *simultaneous* oral administration of the two drugs leads to a peak separation of ~4 h with minimal evidence of pharmacokinetic or pharmacodynamic drug–drug interactions (NCT01290276, clinicaltrials.gov). Ondansetron was selected for the formulation development and the clinical trials based on the considerations that this antagonist: (1) has been the most extensively characterized in our preclinical models; (2) has been used in clinical practice with minimal side effects; and (3) has shown efficacy in selected clinical studies in reducing alcohol or cocaine, but not METH use (Johnson et al., 2006, 2008; Johnson, 2010). Finally, the ready availability of generic ondansetron provides a practical advantage for expediting the development and potential approval of novel temporally-released formulations. In addition to clinical tools (e.g., Cocaine Selective Severity Assessment), functional magnetic resonance imaging is being used to assess the treatment outcome in abstinent cocaine and/or methamphetamine abusers residing in a local residential treatment facility.

8. Summary

Under the combination treatment regimen described in this review, the consolidated psychostimulant-abuse circuit is repeatedly reactivated and rendered labile by daily administration of a clinically-available psychostimulant or a psychostimulant substitute. Subsequent administration of a 5-HT₃, 5-HT₂, or NK-1 antagonist within a critical time window, in turn, disrupts reconsolidation and restabilization of the addiction circuit. Such a process-targeting treatment may reverse the underlying neurobiological processes that maintain the psychostimulant abuse and thus may offer the potential for a more effective intervention, rather than palliative treatment strategies. Sequential or programmed administration of two drugs at a fixed time-interval to target reactivation and reconsolidation of psychostimulant-abuse memory circuit is a novel example of targeting a critical time-window to achieve the desired therapeutic outcome.

Acknowledgments

We would like to thank David A. Gorelick, M.D., Ph.D., Intramural Research Program, NIDA for his comments on the manuscript. This article was overviewed at the American Psychiatry Association Meeting in New Orleans, Louisiana, in 2010 and the NCDEU Meeting in Boca Raton, Florida, in 2010 (Young Investigator Awards presented to STS). This review is dedicated to the memory of Everett H. Ellinwood, Jr., M.D.

Role of funding source

Supported by R01-DA06519, R01-DA012768, R01-DA014323 and RC2-DA028905 from the National Institute on Drug Abuse.

References

Anderson AL, Reid MS, Li SH, Holmes T, Shemanski L, Slee A, Smith EV, Kahn R, Chiang N, Vocci F, Ciraulo D, Dackis C, Roache JD, Salloum IM, Somoza E, Urschel HC 3rd, Elkashef AM.

- Modafinil for the treatment of cocaine dependence. *Drug Alcohol Depend.* 2009; 104:133–139. [PubMed: 19560290]
- Angrist BM, Gershon S. The phenomenology of experimentally induced amphetamine psychosis—preliminary observations. *Biol Psychiatry.* 1970; 2:95–107. [PubMed: 5459137]
- Bernardi RE, Lattal KM, Berger SP. Anisomycin disrupts a contextual memory following reactivation in a cocaine-induced locomotor activity paradigm. *Behav Neurosci.* 2007; 121:156–163. [PubMed: 17324060]
- Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. *Nat Rev Mol Cell Biol.* 2003; 4:517–529. [PubMed: 12838335]
- Bhatia KS, Szabo ST, Fowler JC, Wetsel WC, Lee TH. Reversal of long-term methamphetamine sensitization by combination of pergolide with ondansetron or ketanserin, but not mirtazapine. *Behav Brain Res.* 2011; 223:227–232. [PubMed: 21571009]
- Barnes JM, Costall B, Coughlan J, Domeney AM, Gerrard PA, Kelly ME, Naylor RJ, Onaivi ES, Tomkins DM, Tyers MB. The effects of ondansetron, a 5-HT₃ receptor antagonist, on cognition in rodents and primates. *Pharmacol Biochem Behav.* 1990; 35:955–962. [PubMed: 2140610]
- Barros HM, Miczek KA. Withdrawal from oral cocaine in rats: ultrasonic vocalizations and tactile startle. *Psychopharmacology (Berl).* 1996; 125:379–384. [PubMed: 8826543]
- Centonze D, Siracusano A, Calabresi P, Bernardi G. Removing pathogenic memories: a neurobiology of psychotherapy. *Mol Neurobiol.* 2005; 32:123–132. [PubMed: 16215277]
- Chen Q, Lee TH, Wetsel WC, Sun QA, Liu Y, Davidson C, Xiong X, Ellinwood EH, Zhang X. Reversal of cocaine sensitization-induced behavioral sensitization normalizes GAD67 and GABAA receptor alpha2 subunit expression, and PKC zeta activity. *Biochem Biophys Res Commun.* 2007; 356:733–738. [PubMed: 17382295]
- Chen Q, Xiong X, Lee TH, Liu Y, Wetsel WC, Zhang X. Neural plasticity and addiction: integrin-linked kinase and cocaine behavioral sensitization. *J Neurochem.* 2008; 107:679–689. [PubMed: 18702665]
- Chen Q, Zhu X, Zhang Y, Wetsel WC, Lee TH, Zhang X. Integrin-linked kinase is involved in cocaine sensitization by regulating PSD-95 and synapsin I expression and GluR1 Ser⁸⁴⁵ phosphorylation. *J Mol Neurosci.* 2010; 40:284–294. [PubMed: 19629758]
- Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP. Limbic activation during cue-induced cocaine craving. *Am J Psychiatry.* 1999; 156:11–18. [PubMed: 9892292]
- Cho AK, Melega WP, Kuczenski R, Segal DS. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. *Synapse.* 2001; 39:161–166. [PubMed: 11180503]
- Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. *Curr HIV/AIDS Rep.* 2005; 2:194–199. [PubMed: 16343378]
- Connell, PH. *Amphetamine Psychosis* (Maudsley Monographs No. 5). Chapman & Hall; London: 1958.
- Contoreggi C, Herning RI, Koeppl B, Simpson PM, Negro PJ Jr, Fortner-Burton C, Hess J. Treatment-seeking inpatient cocaine abusers show hypothalamic dysregulation of both basal prolactin and cortisol secretion. *Neuroendocrinology.* 2003; 78:154–162. [PubMed: 14512708]
- Costall B, Jones BJ, Kelly ME, Naylor RJ, Onaivi ES, Tyers MB. Sites of action of ondansetron to inhibit withdrawal from drugs of abuse. *Pharmacol Biochem Behav.* 1990; 36:97–104. [PubMed: 2140900]
- Cruikshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. *Addiction.* 2009; 104:1087–1099.
- Darke, S.; Kaye, S.; McKetin, R.; Duffou, J. *Physical and Psychological Harms of Psychostimulant Use: NDARC Technical Report No. 286*. National Drug and Alcohol Research Centre; Sydney: 2007.
- Davidson C, Gopalan R, Ahn C, Chen Q, Mannelli P, Patkar AA, Weese GD, Lee TH, Ellinwood EH. Reduction in methamphetamine induced sensitization and reinstatement after combined pergolide plus ondansetron treatment during withdrawal. *Eur J Pharmacol.* 2007; 565:113–118. [PubMed: 17408614]

- Davidson C, Lazarus C, Lee TH, Ellinwood EH. Behavioral sensitization is greater after repeated versus single chronic cocaine dosing regimens. *Eur J Pharmacol.* 2002a; 441:75–78. [PubMed: 12007922]
- Davidson C, Lazarus C, Xiong X, Lee TH, Ellinwood EH. 5-HT₂ antagonists given in the acute withdrawal from daily cocaine injections reverse established sensitization. *Eur J Pharmacol.* 2002b; 453:255–263. [PubMed: 12398913]
- Davidson C, Lee TH, Ellinwood EH. The NK(1) receptor antagonist WIN51708 reduces sensitization after chronic cocaine. *Eur J Pharmacol.* 2004; 499:355–356. [PubMed: 15381058]
- Davidson C, Lee TH, Xiong Z, Ellinwood EH. Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration. *Neuropsychopharmacology.* 2002c; 27:542–553. [PubMed: 12377391]
- de Leeuw AS, Westenberg HG. Hypersensitivity of 5-HT₂ receptors in OCD patients. An increased prolactin response after a challenge with metachlorophenylpiperazine and pre-treatment with ritanserin and placebo. *J Psychiatr Res.* 2008; 42:894–901. [PubMed: 18533183]
- Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. *Am J Psychiatry.* 1991; 148:224–230. [PubMed: 1987823]
- Donovan E. Propranolol use in the prevention and treatment of posttraumatic stress disorder in military veterans: forgetting therapy revisited. *Perspect Biol Med.* 2010; 53:61–74. [PubMed: 20173296]
- Drake RE, Wallach MA. Substance abuse among the chronic mentally ill. *Hosp Community Psychiatry.* 1989; 45:1041–1045. [PubMed: 2807205]
- D'Souza MS, Markou A. Neural substrates of psychostimulant withdrawal-induced anhedonia. *Curr Top Behav Neurosci.* 2010:119–178. [PubMed: 21161752]
- Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J. Pharmacotherapy of methamphetamine addiction: an update. *Subst Abuse.* 2008; 29:31–49.
- Ellinwood EH Jr. Amphetamine psychosis: II. Theoretical implications. *Int J Neuropsychiatry.* 1968; 4:45–54. [PubMed: 5645819]
- Ellinwood, EH.; Lee, TH. Dose- and time-dependent effects of stimulants. In: Asgjar, K.; De Souza, E., editors. *Pharmacology and Toxicology of Amphetamine and Related Designer Drugs.* Vol. 94. NIDA Monograph; 1989. p. 323–340.
- Ellinwood EH, Davidson C, Yu GZ, King GR, Lee TH. Effect of daily dosing duration of direct and indirect dopamine receptor agonists: cocaine cross-tolerance following chronic regimens. *Eur Neuropsychopharmacol.* 2002; 12:407–415. [PubMed: 12208558]
- European Monitoring Centre for Drugs and Drug Addiction. Amphetamines, ecstasy and hallucinogenic substances. Annual report 2010: The State of the Drugs Problem in Europe. Luxembourg. 2010
- Foltin RW, Fischman MW. Residual effects of repeated cocaine smoking in humans. *Drug Alcohol Depend.* 1997; 47:117–124. [PubMed: 9298333]
- Fricks-Gleason AN, Marshall JF. Post-retrieval beta-adrenergic receptor blockade: effects on extinction and reconsolidation of cocaine-cue memories. *Learn Mem.* 2008; 26:643–648. [PubMed: 18772251]
- Fukushiro DF, Alvarez Jdo N, Tatsu JA, de Castro JP, Chinen CC, Frussa-Filho R. Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice. *Prog Neuropsychopharmacol Biol Psychiatry.* 2007; 31:867–872. [PubMed: 17368685]
- Fukushiro DF, Mari-Kawamoto E, Aramini TC, Saito LP, Costa JM, Josino FS, Frussa-Filho R. Withdrawal from repeated treatment with amphetamine reduces novelty-seeking behavior and enhances environmental habituation in mice. *Pharmacol Biochem Behav.* 2011; 100:180–184. [PubMed: 21875614]
- Fung YK, Richard LA. Behavioural consequences of cocaine withdrawal in rats. *J Pharm Pharmacol.* 1994; 46:150–152. [PubMed: 8021807]
- Gawin FH, Ellinwood EH Jr. Cocaine and other stimulants. Actions, abuse, and treatment. *N Engl J Med.* 1988; 318:1173–1182. [PubMed: 3283549]
- Gawin FH, Kleber HD. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. *Arch Gen Psychiatry.* 1986; 43:107–113. [PubMed: 3947206]

- Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson RA. Methamphetamine treatment project corporate authors, psychopathology in methamphetamine-dependent adults 3 years after treatment. *Drug Alcohol Rev.* 2010; 29:12–20. [PubMed: 20078677]
- Gonzales R, Marinelli-Casey P, Shoptaw S, Ang A, Rawson RA. Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment. *J Subst Abuse Treat.* 2006; 31:195–202. [PubMed: 16919748]
- Grant KA. The role of 5-HT₃ receptors in drug dependence. *Drug Alcohol Depend.* 1995; 38:155–171. [PubMed: 7671767]
- Hall W, Gartner C. Ethical and policy issues in using vaccines to treat and prevent cocaine and nicotine dependence. *Curr Opin Psychiatry.* 2011; 24:191–196. [PubMed: 21430537]
- Haney M, Foltin RW, Fischman MW. Effects of pergolide on intravenous cocaine self-administration in men and women. *Psychopharmacology (Berl).* 1998; 137:15–24. [PubMed: 9631952]
- Jaffe JH, Cascella NG, Kumor KM, Sherer MA. Cocaine-induced cocaine craving. *Psychopharmacology (Berl).* 1989; 97:59–64. [PubMed: 2496428]
- Jakab RL, Goldman-Rakic PS. Segregation of serotonin 5-HT_{2A} and 5-HT₃ receptors in inhibitory circuits of the primate cerebral cortex. *J Comp Neurol.* 2000; 417:337–348. [PubMed: 10683608]
- Jakab RL, Goldman-Rakic PS, Leranath C. Dual role of substance P/GABA axons in cortical neurotransmission: synaptic triads on pyramidal cell spines and basket-like innervation of layer II–III calbindin interneurons in primate prefrontal cortex. *Cereb Cortex.* 1997; 7:359–373. [PubMed: 9177766]
- Janowsky DS, Davis JM. Dopamine, psychomotor stimulants, and schizophrenia: effects of methylphenidate and the stereoisomers of amphetamine in schizophrenics. *Adv Biochem Psychopharmacol.* 1974; 12:317–323. [PubMed: 4608582]
- Janowsky DS, Risch C. Amphetamine psychosis and psychotic symptoms. *Psychopharmacology.* 1979; 65:73–77. [PubMed: 116294]
- Jeffcoat AR, Perez-Reyes M, Hill JM, Sadler BM, Cook CE. Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking. *Drug Metab Dispos.* 1989; 17:153–159. [PubMed: 2565204]
- Johnson BA. Medication treatment of different types of alcoholism. *Am J Psychiatry.* 2010; 167:630–639. [PubMed: 20516163]
- Johnson BA, Ait-Daoud N, Elkashef AM, Smith EV, Kahn R, Vocci F, Li SH, Bloch DA. Methamphetamine Study Group. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. *Int J Neuropsychopharmacol.* 2008; 11:1–14. [PubMed: 17470315]
- Johnson BA, Roache JD, Ait-Daoud N, Javors MA, Harrison JM, Elkashef A, Mojsiak J, Li SH, Bloch DA. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. *Drug Alcohol Depend.* 2006; 84:256–263. [PubMed: 16631323]
- Kampman KM, Alterman AI, Volpicelli JR, Maany I, Muller ES, Luce DD, Mulholland EM, Jawad AF, Parikh GA, Mulvaney FD, Weinrieb RM, O'Brien CP. Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. *Psychol Addict Behav.* 2001; 15:52–59. [PubMed: 11255939]
- Kelley JB, Anderson KL, Itzhak Y. Long-term memory of cocaine-associated context: disruption and reinstatement. *Neuroreport.* 2007; 18:777–780. [PubMed: 17471065]
- Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. *Lancet.* 2000; 355:911–918. [PubMed: 10752718]
- Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. *Am J Psychiatry.* 1985; 142:1259–1264. [PubMed: 3904487]
- King GR, Xiong Z, Douglass S, Ellinwood EH. Long-term blockade of the expression of cocaine sensitization by ondansetron, a 5-HT(3) receptor antagonist. *Eur J Pharmacol.* 2000; 394:97–101. [PubMed: 10771040]
- King GR, Xiong Z, Ellinwood EH, King GR, Xiong Z, Ellinwood EH Jr. Blockade of the expression of sensitization and tolerance by ondansetron, a 5-HT₃ receptor antagonist, administered during

- withdrawal from intermittent and continuous cocaine. *Psychopharmacology* (Berl). 1998; 135:263–269. [PubMed: 9498729]
- Kinsey BM, Kosten TR, Orson FM. Anti-cocaine vaccine development. *Expert Rev Vaccines*. 2010; 9:1109–1114. [PubMed: 20822352]
- Koeltzow TE, White FJ. Behavioral depression during cocaine withdrawal is associated with decreased spontaneous activity of ventral tegmental area dopamine neurons. *Behav Neurosci*. 2003; 117:860–865. [PubMed: 12931970]
- Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. *Neuropsychopharmacology*. 2001; 24:97–29. [PubMed: 11120394]
- Koob GF, Volkow ND. Neurocircuitry of addiction. *Neuropsychopharmacology*. 2010; 35:217–238. [PubMed: 19710631]
- Kreitzer AC, Malenka RC. Striatal plasticity and basal ganglia circuit function. *Neuron*. 2008; 60:543–554. [PubMed: 19038213]
- Kuribara H. Can posttreatment with the selective dopamine D2 antagonist, YM-09151-2, inhibit induction of methamphetamine sensitization? Evaluation by ambulatory activity in mice. *Pharmacol Biochem Behav*. 1994; 49:323–326. [PubMed: 7824544]
- Kuribara H. Inhibition of methamphetamine sensitization by postmethamphetamine treatment with SCH 23390 or haloperidol. *Psychopharmacology*. 1995; 119:34–38. [PubMed: 7675947]
- Landén M, Thase ME. A model to explain the therapeutic effects of serotonin reuptake inhibitors: the role of 5-HT2 receptors. *Psychopharmacol Bull*. 2006; 39:147–166. [PubMed: 17065978]
- LeDuc PA, Mittleman G. Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. *Psychopharmacology*. 1995; 121:407–427. [PubMed: 8619004]
- Lee JL, Di Ciano P, Thomas KL, Everitt BJ. Disrupting reconsolidation of drug memories reduces cocaine-seeking behavior. *Neuron*. 2005; 47:795–801. [PubMed: 16157275]
- Lee JL, Milton AL, Everitt BJ. Cue-induced cocaine seeking and relapse are reduced by disruption of drug memory reconsolidation. *J Neurosci*. 2006; 26:5881–5887. [PubMed: 16738229]
- Lee TH, Gao WY, Davidson C, Ellinwood EH. Altered activity of midbrain dopamine neurons following 7-day withdrawal from chronic cocaine abuse is normalized by D2 receptor stimulation during the early withdrawal phase. *Neuropsychopharmacology*. 1999; 21:127–136. [PubMed: 10379527]
- Leventhal AM, Kahler CW, Ray LA, Stone K, Young D, Chelminski I, Zimmerman M. Anhedonia and amotivation in psychiatric outpatients with fully remitted stimulant use disorder. *Am J Addict*. 2008; 17:218–223. [PubMed: 18463999]
- Levin FR, McDowell D, Evans SM, Brooks D, Spano C, Nunes EV. Pergolide mesylate for cocaine abuse: a controlled preliminary trial. *Am J Addict*. 1999; 8:120–127. [PubMed: 10365192]
- Lewis DA, González-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. *Neuropsychopharmacology*. 2008; 33:141–165. [PubMed: 17805309]
- Li Y, White FJ, Wolf ME. Pharmacological reversal of behavioral and cellular indices of cocaine sensitization in the rat. *Psychopharmacology*. 2000; 151:175–183. [PubMed: 10972463]
- Mahoney JJ 3rd, Kalechstein AD, De La Garza R 2nd, Newton TF. Presence and persistence of psychotic symptoms in cocaine- versus methamphetamine-dependent participants. *Am J Addict*. 2008; 17:83–98. [PubMed: 18393050]
- Malcolm R, Kajdasz DK, Herron J, Anton RF, Brady KT. A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. *Drug Alcohol Depend*. 2000; 60:161–168. [PubMed: 10940543]
- Mantsch JR, Taves S, Khan T, Katz ES, Sajan T, Tang LC, Cullinan WE, Ziegler DR. Restraint-induced corticosterone secretion and hypothalamic CRH mRNA expression are augmented during acute withdrawal from chronic cocaine administration. *Neurosci Lett*. 2007; 415:269–273. [PubMed: 17293045]
- Miller FT, Tanenbaum JH. Drug abuse in schizophrenia. *Hosp Community Psychiatry*. 1989; 40:847–849. [PubMed: 2788120]
- Mulvaney FD, Alterman AI, Boardman CR, Kampman K. Cocaine abstinence symptomatology and treatment attrition. *J Subst Abuse Treat*. 1999; 16:129–135. [PubMed: 10023610]

- Mutschler NH, Miczek KA. Withdrawal from a self administered or noncontingent cocaine binge – differences in ultrasonic distress vocalizations in rats. *Psychopharmacology (Berl)*. 1998; 136:402–408. [PubMed: 9600587]
- Nader K, Hardt O. A single standard for memory: the case for reconsolidation. *Nat Rev Neurosci*. 2009; 10:224–234. [PubMed: 19229241]
- Newton TF, Kalechstein AD, Duran S, Vansluis N, Ling W. Methamphetamine abstinence syndrome: preliminary findings. *Am J Addict*. 2004; 13:248–255. [PubMed: 15370944]
- Newton TF, Kalechstein AD, Tervo KE, Ling W. Irritability following abstinence from cocaine predicts euphoric effects of cocaine administration. *Addict Behav*. 2003; 28:817–321. [PubMed: 12726795]
- Pierce RC, Vanderschuren LJ. Kicking the habit: the neural basis of ingrained behaviors in cocaine addiction. *Neurosci Biobehav Rev*. 2010; 35:212–219. [PubMed: 20097224]
- Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. *Neuropsychopharmacology*. 2008; 33:88–109. [PubMed: 17851537]
- Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. *JAMA*. 1990; 264:2511–2518. [PubMed: 2232018]
- Robinson TE, Berridge KC. Review. The incentive sensitization theory of addiction: some current issues. *Philos Trans R Soc Lond B: Biol Sci*. 2008; 363:3137–3146. [PubMed: 18640920]
- Sadler R, Herzig V, Schmidt WJ. Repeated treatment with the NMDA antagonist MK-801 disrupts reconsolidation of memory for amphetamineconditioned place preference. *Behav Pharmacol*. 2007; 18:699–703. [PubMed: 17912055]
- Sarnyai Z, Dhabhar FS, McEwen BS, Kreek MJ. Neuroendocrinerelated effects of long-term ‘binge’ cocaine administration: diminished individual differences in stress-induced corticosterone secretion. *Neuroendocrinology*. 1998; 68:334–344. [PubMed: 9822801]
- Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. *N Engl J Med*. 2007; 356:29–38. [PubMed: 17202453]
- Schiller D, Monfils MH, Raio CM, Johnson DC, Ledoux JE, Phelps EA. Preventing the return of fear in humans using reconsolidation update mechanisms. *Nature*. 2010; 463:36–37. [PubMed: 20054384]
- Shalev U, Grimm JW, Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: a review. *Pharmacol Rev*. 2002; 54:1–42. [PubMed: 11870259]
- Sinha R. How does stress increase risk of drug abuse and relapse? *Psychopharmacology*. 2001; 158:343–539. [PubMed: 11797055]
- Sinha R, Garcia M, Paliwal P, Kreek MJ, Rounsaville BJ. Stress-induced cocaine craving and hypothalamic–pituitary–adrenal responses are predictive of cocaine relapse outcomes. *Arch Gen Psychiatry*. 2006; 63:324–331. [PubMed: 16520439]
- Sofuoglu M, Dudish-Poulsen S, Brown SB, Hatsukami DK. Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine. *Drug Alcohol Depend*. 2003; 69:273–282. [PubMed: 12633913]
- Steketee JD, Kalivas PW. Drug wanting: behavioral sensitization and relapse to drug-seeking behavior. *Pharmacol Rev*. 2011; 63:348–365. [PubMed: 21490129]
- Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS), 1996–2006. National Admissions to Substance Abuse Treatment Services. Rockville, MD: 2008. DASIS Series: S-43, DHHS Publication No SMA 08-4347
- Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug abuse warning network, 2007. National estimates of drug-related emergency department visits. Rockville, MD: 2010.
- Substance Abuse and Mental Health Services Administration. Results from the 2008 national survey on drug use and health. National findings. Rockville, MD: 2009. Office of Applied Studies, NSDUH Series H-36, HHS Publication No SMA 09-4434
- Taylor WA, Gold MS. Pharmacologic approaches to the treatment of cocaine dependence. *West J Med*. 1990; 152:573–577. [PubMed: 1971975]

- Volkow ND. Substance use disorders in schizophrenia – clinical implications of comorbidity. *Schizophr Bull.* 2009; 35:469–472. [PubMed: 19325163]
- Zhang X, Lazarus C, Wetsel WC, Davidson C, Lee TH, Ellinwood EH. Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors. *Neuropsychopharmacology.* 2007; 32:377–387. [PubMed: 16794574]

\$watermark-text

\$watermark-text

\$watermark-text

Fig. 1.

(A) Behavioral sensitization paradigm. Sprague-Dawley rats are treated with either cocaine or METH to induce sensitization and withdrawn for 7–14 days to establish behavioral sensitization (consolidation). Subsequently, they are given a control or agonist/antagonist combination treatment for seven days, followed by a second withdrawal period to wash out the treatment drugs. On the acute challenge day, cocaine- and METH-sensitized animals are acutely challenged with their respective sensitization drug, and are sacrificed on the following day for neurobiological marker measurements. Psychostimulants themselves (cocaine and METH) and pergolide have been used as DA agonists, while ondansetron (5-HT₃), ketanserin/mianserin (5-HT_{2A/2C}), clozapine (5-HT₃, 5-HT_{2A/2B} and other receptor subtypes) and WIN51708 (NK1) are antagonists that have shown efficacy in combinations with the agonist. (B) Drug-induced self-administration (SA) reinstatement paradigm. Similar to behavioral sensitization, rats are trained to nose-poke for cocaine or METH, withdrawn establish SA (consolidation), and subsequently treated with a combination treatment. Upon the treatment completion, rats undergo extinction followed by drug-induced reinstatement procedure. Tissue samples are collected one day after the last reinstatement testing. Combinations of pergolide and ondansetron have shown to reduced drug-induced reinstatement.

Fig. 2.

Hypothesized therapeutic erasure of consolidated psychostimulant (ψ STIM) abuse memory. In untreated psychostimulant abusers, the stable memory is reactivated by exposure to various stimuli such as psychostimulants themselves, environmental cues associated with drug use or "stress" (arrow). Unless interfered with, the reactivated memory becomes reconsolidated during withdrawal. A therapeutically-delivered DA agonist is also hypothesized to reactivate the consolidated psychostimulant abuse memory. The transiently-reactivated circuit is labile and can be disrupted by delayed administration of a 5-HT₃, 5-HT_{2A/2C} or NK-1 antagonist that blocks reconsolidation (X). This reconsolidation blockade leads to "erasure" of the dysfunctional memory (open arrow).

Table 1

Changes in the protein expression levels of selected neurobiological markers in the prefrontal cortex (PFC) and nucleus accumbens core (NAc Core) that are associated with consolidated cocaine sensitization and self-administration (S-A). Pergolide/ondansetron combination treatment normalizes these changes.

	PFC	NAc Core	References
NR2B NMDA receptor subunit	NC	NC	Zhang et al. (2007)
NR2B Tyr ¹⁴⁷² phosphorylation	NC	(-)	Zhang et al. (2007)
GluR1 AMPA receptor subunit	NC	NC	Zhang et al. (2007)
GluR1 Ser ⁸³¹ phosphorylation	NC	NC	Zhang et al. (2007)
GluR1 Ser ⁸⁴⁵ phosphorylation	(+)	(+)	Zhang et al. (2007) and Chen et al. (2010)
GluR1 Ser ⁸⁴⁵ phosphorylation (S-A)	(+)	(+)	Zhang et al. (2007) and Chen et al. (2010)
Brain-derived neurotrophic factor	(+)	(+)	Unpublished results
Integrin-linked kinase	(+)	(+)	Chen et al. (2008) and unpublished results
Protein kinase B (Akt)	NC	NC	Chen et al. (2008) and unpublished results
Akt Thr ³⁰⁸ Phosphorylation	NC	NC	Unpublished results
Akt Ser ⁴⁷⁸ Phosphorylation	(+)	(+)	Chen et al. (2008) and unpublished results
Protein kinase C (PKC) ζ	N/D	(+)	Chen et al. (2007)
PKC ζ (S-A)	N/D	(+)	Unpublished results
PKC ζ Thr ⁴¹⁰ Phosphorylation	N/D	(+)	Chen et al. (2007)

(+), increased vs. non-sensitized animals; (-), decreased vs. non-sensitized animals; NC, no change; N/D, not determined.